Clinical AI startup Abridge held a New York City event to signal it's done being thought of as just an AI scribe. The company announced a Nvidia foundation model partnership, an Eli Lilly investment, new capabilities for its platform, and the intent to help mediate the relationship between payers and providers.
Nvidia and Hoppr are betting that healthcare AI will scale not through standalone applications, but through a new infrastructure layer that lets providers develop and deploy their own imaging models.
What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes.
The conversation between MedCity News Editor-in-Chief Arundhati Parmar and Samir Batra, managing partner of Health Innovation Pitch, highlighted news from the J.P. Morgan Healthcare Conference, particularly how technology and biopharma companies are shaping AI in healthcare.
Jensen Huang, CEO of Nvidia and David Ricks, CEO of Eli Lilly, discussed their recently-announced partnership and the potential of GLP-1s at an event in San Francisco.
This year's J.P. Morgan Healthcare Conference brought a slew of news announcements — from acquisitions to partnerships to new products and more. This list compiles short summaries for six of the event’s most notable announcements.
At JPM, Nvidia unveiled partnerships with Eli Lilly, Thermo Fisher and others that show how the chipmaker is pushing its AI beyond models and into the core infrastructure of drug discovery and research labs. The moves highlight Nvidia’s ambitions to become a foundational technology provider for the pharma industry.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
Agentic AI is emerging as “hireable” digital labor in healthcare, according to Nvidia’s Kimberly Powell. She argued that once health system leaders stop viewing AI as software and start treating it as a workforce asset, the technology could rapidly reduce burnout and expand access to care.
Nvidia has quietly become one of the most influential players in healthcare technology by supplying the accelerated computing and AI infrastructure that powers everything from imaging to drug discovery. The company’s restraint — focusing on enabling the ecosystem rather than owning it — has helped cement its role as the indispensable backbone of the healthcare industry’s AI transformation.
Healthcare organizations are starting to implement AI agents — autonomous, task-specific systems designed to perform functions with little or no human intervention. While initial adoption is focused mainly on non-clinical areas like scheduling and prior authorizations, experts predict that AI agents could eventually play a role in clinical decision-making, provided they meet rigorous safety and reliability standards.
At JPM25, Nvidia announced four new partnerships focused on scaling AI models across the healthcare industry. The company is teaming up with Mayo Clinic, Illumina, IQVIA and Arc Institute.
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
Here are nine notable announcements shared at the HLTH conference held this week in Las Vegas.
At RSNA 2023, Nvidia launched new set of cloud-based APIs designed to speed up the creation and deployment of specialized AI models in the medical imaging field. The new offering is a cloud-native extension to Nvidia's Monai framework, which is its open-source framework for medical imaging AI.
Nvidia’s investment isn’t just working capital for Recursion Pharmaceuticals’ technology-driven drug discovery research. Recursion says it will get more computing power as well as the possibility of joining forces with Nvidia in research.
Nvidia and Medtronic recently announced a collaboration focused on embedding AI into medical devices. The two companies plan to create marketplace for AI applications that will allow developers and clinicians to develop their own algorithms to use on Medtronic’s medical devices.
A collaboration between Nvidia and startup Evozyne was able to produce novel versions of a human protein never before seen in nature but with enhanced function and the same safety as native protein. The research lays the groundwork for potential new therapies for a rare inherited disorder.